Selective targeting of tumor vasculature using antibody molecules
CA 2478414 C · Owner: Friebe, Matthias · Inventors: Hilger, Christoph-Stephan; Zardi, Luciano; Friebe, Matthias
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to selectively targeting tumoral vasculature in vivo using a human recombinant scFv, L19 to the angiogenesis marker ED-B , domain of fibronectin. In preferred embodiments a complete human IgG1 is , employed having the variable regions of L19. In other embodiments is employed a mini-immunoglobulin generated by fusing the scFv L19 to the constant CH4 domain of a secretory IgE isoform that naturally contains a cysteine in its COOH terminal and which forms a covalently linked dimer. Different in vivo behaviour of the antibody formats is exploitable for different diagnostic and/or therapeutic purposes, depending on clinical needs and disease. The antibody …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 11, 2003 and granted November 13, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 11, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 11, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.